AIS CELLector CD5/CD8 data

AISX (Santa Clara, Calif.) reported at the Nashville meeting of the American Society of Hematology preliminary Phase II results suggesting a lowered rate of acute reaction in a high-risk population.

Of 17 patients with advanced refractory leukemia, only two of the 15 whose transplant engrafted developed grade III disease. The expected rate of this complication is 50 percent, the company said. ...